CareDx To Participate In Upcoming Investor Conferences

BRISBANE, Calif., Nov. 08, 2016 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today announced that Dr. Peter Maag, Chief Executive Officer, and Charles Constanti, Chief Financial Officer, will be participating in four upcoming investor conferences:

Mizuho Global Investor Conference in New York City
  • Dr. Peter Maag and Charles Constanti will participate in one-on-one meetings on Monday, November 14, 2016

7 th Annual Craig-Hallum Alpha Select Conference in New York City
  • Dr. Peter Maag and Charles Constanti will present on Wednesday, November 16, 2016 at 11:50am PT/2:50pm ET.

28 th Annual Piper Jaffray Healthcare Conference in New York City
  • Dr. Peter Maag and Charles Constanti will present on Tuesday, November 29, 2016 at 11:00am PT/1:00pm ET.

Evercore ISI MedTools Investor Conference in Boston, MA
  • Dr. Peter Maag and Charles Constanti will participate in one-on-one meetings on December 1, 2016.

A live audio webcast of the Craig-Hallum Alpha Select and Piper Jaffray Healthcare conferences presentations will be available online from the Investor Relations page of the Company's website at http://investors.caredxinc.com. The webcast replay of each presentation will be available on the Company's website for 90 days. Due to the one-on-one only format of the Mizuho and Evercore ISI MedTools conferences, no webcasts will be available.

About CareDxCareDx, Inc., based in Brisbane, California, is a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value, diagnostic solutions for transplant recipients. The Company has commercialized AlloMap ®, a gene expression test that aids clinicians in identifying risk of rejection in heart transplant recipients.

CareDx is also pursuing the development of additional products for post-transplant monitoring of other solid organs that use a variety of technologies, including next generation sequencing, to detect donor-derived cell-free DNA to monitor the health of organs after transplantation. For more information, please visit: www.CareDx.com.

CareDx, with its presence through Olerup, also develops, manufactures, markets and sells high quality products that increase the chance of successful transplants by facilitating a better match between a donor and a recipient of stem cells and organs. For more information, please visit: www.CareDx.com.
Investor Relations ContactJamar Ismail, Vice PresidentWestwicke Partners, LLC T: +1 415-513-1282E: jamar.ismail@westwicke.com

Primary Logo

More from Press Releases

NFL Pushes for Regulation Following Supreme Court's Sports Gambling Ruling

NFL Pushes for Regulation Following Supreme Court's Sports Gambling Ruling

21st Century Fox Scoops Up Local News Stations

21st Century Fox Scoops Up Local News Stations

Walmart CEO: 'We Are Transforming Globally' With Flipkart

Walmart CEO: 'We Are Transforming Globally' With Flipkart

Three-Part FREE Webinar Series

Three-Part FREE Webinar Series

March 24 Full-Day Course Offering: Professional Approach to Trading SPX

March 24 Full-Day Course Offering: Professional Approach to Trading SPX